Combination treatment before and after surgery for liver cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of three drugs given before and after surgery for liver cancer that can be removed. The goal is to see if this approach can help reduce the chance of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with hepatocellular carcinoma (the most common type of liver cancer).
- You have not had any prior treatment for your liver cancer.
- You are generally in good health (able to care for yourself, with a performance status of 0 or 1).
- Your liver function is good (Child-Pugh class A).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether combining a standard treatment for liver cancer (TACE) with three additional medications can help people whose cancer cannot be cured. The goal is to see if the combination is more effective than TACE alone.
This trial tests a new combination of three drugs (SHR-8068, adebrelimab, and bevacizumab) against two standard immunotherapy combinations (sintilimab or atezolizumab plus bevacizumab) for people with advanced liver cancer who haven't had systemic treatment before. The goal is to see if the new combo works better for shrinking or controlling the cancer.
This trial tests a combination of immunotherapy drugs, radiation therapy, and a targeted therapy drug before and after surgery for people with intermediate-stage liver cancer that can be surgically removed. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a combination of two medicines (adebrelimab and apatinib) for people with advanced liver cancer who have already tried other treatments. The goal is to see if this combo can slow down the cancer and improve outcomes.
This trial tests a combination of focused radiation (SBRT), an immunotherapy drug (adelimumab), and a targeted therapy pill (apatinib) for liver cancer that can be removed with surgery. The goal is to see if this combination can shrink tumors before surgery and help prevent the cancer from coming back.
This trial tests if giving a combination of drugs (apatinib and camrelizumab) along with a procedure called TACE before surgery can help treat a certain type of liver cancer. The goal is to shrink the tumor before the operation to improve outcomes.
Hear when a new Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.